Thermo Fisher Scientific Inc. $TMO Shares Sold by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,074 shares of the medical research company’s stock after selling 197 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,829,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC lifted its position in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $31,000. IMA Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $35,000. Finally, DiNuzzo Private Wealth Inc. raised its position in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $574.15, for a total value of $229,660.00. Following the transaction, the executive vice president owned 21,152 shares of the company’s stock, valued at approximately $12,144,420.80. This represents a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 17,104 shares of the firm’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $573.54, for a total value of $9,809,828.16. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This represents a 13.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 36,420 shares of company stock worth $19,980,884. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 1.2%

Shares of TMO stock opened at $572.72 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a market cap of $215.18 billion, a PE ratio of 33.09, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The business’s fifty day moving average is $518.58 and its 200-day moving average is $462.80. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period in the previous year, the company earned $5.28 earnings per share. Thermo Fisher Scientific’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on TMO shares. Robert W. Baird upped their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Citigroup increased their price objective on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, HSBC reiterated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Nineteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.